The role of MDSCs in hepatocellular carcinoma--in vivo veritas?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Immunotherapy for hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2024
   Review
2. Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells.Oncogene · 2022
   Article
3. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.Cellular immunology · 2021
   Review
4. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update.Cancers · 2020
   Review
5. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2020
   Review
6. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.Gut · 2018
   Article
7. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.World journal of gastroenterology · 2018
   Review
8. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2016
   Review
9. Adaptive immunity in the liver.Cellular & molecular immunology · 2016
   Review
10. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.BioMed research international · 2015
    Review
11. Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma.Oncoimmunology
    Article

Corrections and comments

• Comment on
  Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as